A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group study in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects must have a documented history of inadequate response to topical AD …

CONDITION: Skin

GENDER: Both males and females

AGE GROUP: 12 and above

TRIAL STATUS: Active, not recruiting

Adolescent Atopic Dermatitis Trial (72 Weeks)

Youth aged 12 to 17 with a history of eczema (atopic dermatitis) for at least one year, may qualify to participate in this study. Adolescents must have moderate to severe …

CONDITION: Skin

GENDER: Both males and females

AGE GROUP: 12 to 17 years

TRIAL STATUS: Active, not recruiting

CAIN457A3404 (REALIA)

Title: A non-interventional, prospective 12 months study to characterize the REAL-life effectiveness and treatment patterns of Secukinumab and current standard of care in patient with chronic plaque psoriAsis eligible for …

CONDITION: Skin

GENDER: Both males and females

AGE GROUP: 18 and above

TRIAL STATUS: Active, not recruiting